Objective： To investigate the adjuvant therapeutic effects of fermented red ginseng（FRG） extract on non-small cell lung cancer（NSCLC） patients treated with chemotherapy. Methods： A total of 60 patients with adva...Objective： To investigate the adjuvant therapeutic effects of fermented red ginseng（FRG） extract on non-small cell lung cancer（NSCLC） patients treated with chemotherapy. Methods： A total of 60 patients with advanced NSCLC were assigned to two groups using a random number table, i.e., the gemcitabine plus cisplatin（GP） chemotherapy alone group（26 patients） and the FRG ＋ GP chemotherapy group（34 patients）, for 60-day treatment. Patients were then assessed according to the Fatigue Symptom Inventory, Chinese medicine symptoms score, Self-Rating Anxiety Scale, Self-Rating Depression Scale, Karnofsky Performance Status Scale, and Functional Assessment of Cancer Therapy-Lung. In addition, chemotherapy toxicity and tumor biomarkers were measured. Results： For NSCLC patients after chemotherapy, FRG extract significantly improved the FSI score, CM symptoms score, psychological status, physical conditions, and quality of life and reduced chemotherapy toxicity（P〈0.01）, but the expression levels of carcinoembryonic antigen, cytokeratin-19 fragments, and neuron-specific enolase were not significantly different between the chemotherapy alone and the FRG ＋ chemotherapy groups or between pre-and post-treatments（P〉0.05）. Conclusions： This study demonstrated that FRG extract had an adjuvant effect on advanced NSCLC patients treated with chemotherapy. Further studies with a larger sample size will verify the current findings.展开更多
基金Supported in part by a grant from the Major Projects for"Creation of Major New Drugs"of the Ministry of Science and Technology of China(No.2010ZX09102-216)the Korea Joongbu University Research Fund
文摘Objective： To investigate the adjuvant therapeutic effects of fermented red ginseng（FRG） extract on non-small cell lung cancer（NSCLC） patients treated with chemotherapy. Methods： A total of 60 patients with advanced NSCLC were assigned to two groups using a random number table, i.e., the gemcitabine plus cisplatin（GP） chemotherapy alone group（26 patients） and the FRG ＋ GP chemotherapy group（34 patients）, for 60-day treatment. Patients were then assessed according to the Fatigue Symptom Inventory, Chinese medicine symptoms score, Self-Rating Anxiety Scale, Self-Rating Depression Scale, Karnofsky Performance Status Scale, and Functional Assessment of Cancer Therapy-Lung. In addition, chemotherapy toxicity and tumor biomarkers were measured. Results： For NSCLC patients after chemotherapy, FRG extract significantly improved the FSI score, CM symptoms score, psychological status, physical conditions, and quality of life and reduced chemotherapy toxicity（P〈0.01）, but the expression levels of carcinoembryonic antigen, cytokeratin-19 fragments, and neuron-specific enolase were not significantly different between the chemotherapy alone and the FRG ＋ chemotherapy groups or between pre-and post-treatments（P〉0.05）. Conclusions： This study demonstrated that FRG extract had an adjuvant effect on advanced NSCLC patients treated with chemotherapy. Further studies with a larger sample size will verify the current findings.
